Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

J. Sacco, Joseph; D. Carvajal, Richard; O. Butler, Marcus; N. Shoushtari, Alexander; C. Hassel, Jessica; P. Ikeguchi, Alexandra; F. Hernandez‐Aya, Leonel; Nathan, Paul; Hamid, Omid; M. Piulats, Josep; J. Rioth, Matthew; B. Johnson, Douglas; J. Luke, Jason; Espinosa, Enrique; Leyvraz, Serge; Collins, Laura; Holland, C.; Sato, Takami

doi:10.1136/jitc-2024-009028

Public

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

Published in Journal for ImmunoTherapy of Cancer • Jun 1, 2024

Authors:

Joseph J. Sacco

Richard D. Carvajal

Marcus O. Butler

Abstract

BACKGROUND: Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of stud...

Subject

Melanoma

Medicine

Metastatic melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!